The FDA Is Reconsidering Peptides. Here's What That Means

What Happened

In 2023, the FDA placed a group of peptides into Category 2 — a classification that prevents compounding pharmacies from producing them. The reasoning was a mix of limited human trial data, manufacturing concerns, and uncertainty about long-term safety.

Now, advisory panels are evaluating whether several of those peptides should be moved back into a category that allows compounding under physician oversight.

What's Actually Under Review

• BPC-157 — recovery and tissue repair
• TB-500 — soft-tissue healing
• GHK-Cu — skin and connective tissue
• CJC-1295 / Ipamorelin — GH-related
• KPV — anti-inflammatory

Why It Matters

Right now, demand for these peptides is enormous, but most of it exists outside regulated channels. That creates real problems: inconsistent purity, unclear dosing, no traceability.

Bringing supply back inside the regulated system — even partially — would meaningfully change the safety profile of the entire category.

The Bigger Trend

This isn't an isolated decision. It's part of a broader recalibration: regulators are recognizing that prohibition without alternatives just pushes activity underground. Controlled access is starting to look like the more pragmatic path.